My Trading Account โ†’
โ–พ
Trading Profile Active
Active Trader
Verified Trader
โšก My $100K Trading Account โ†’ โ˜… My Saved Watchlist โ†’
๐ŸŸข My $100K Account โ†’ Today Screener ๐Ÿ›๏ธ Insiders
โœ“ Last Updated: Nov 16, 2026 โ€ข Verified SEC EDGAR, 13F & Cboe Data for 2027 RQD Quant Engine v6.2 Live

Bristol-Myers Squibb Company (BMY) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$58.34 -2.06% NYSE โ€ข Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $58.01

Bristol-Myers Squibb Company (BMY) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ โ€ข SELL / AVOID Cap $119.24B
๐Ÿ“ค Share Live RQD Speedometer Card: ๐• Post Reddit StockTwits โฌ‡ Live SVG Card
โšก INSTANT AI QUANT PREVIEW โ€ข $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BMY Below โ€” or Connect Your Own ChatGPT / Claude
๐Ÿค– Mara Quenwick โ€ข AI Quant Lead (Click for Instant Brief) Is BMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
โ–ผ

As of 2026-11-22, Bristol-Myers Squibb Company (NYSE: BMY) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $58.34 (-2.06% 1D, market cap $119.24B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, BMY ranks #183 in composite RQD confidence.

โœ“ Pre-computed one-to-many AI Quant brief
๐Ÿค– Ellis Vennor โ€ข AI Peer & Flow Quant (Click for Instant Brief) How does BMY compare to SNY and VRTX in the Health Care sector?
โ–ผ

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BMY carries a Roarable D+ (54/100 RQD), trailing P/E of 17.8x, gross margin of 71.1%, and ROIC of 13.3%. By comparison, SNY (Sanofi ADS) holds a C grade (62/100 RQD, P/E 32.8x, ROIC 9.9%, cap $112.33B) and VRTX (Vertex Pharmaceuticals Incorporated) posts a B grade (73/100 RQD, P/E 34.6x, ROIC 20.0%, cap $132.01B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).

โœ“ Pre-computed one-to-many AI Quant brief
๐Ÿค– Gideon Ashmere โ€ข AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BMY?
โ–ผ

Per BMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000014272), Bristol-Myers Squibb Company generated $48.19B in revenue (-0.2% YoY), $7.05B in net income, and $12.85B in free cash flow against $90.04B in total assets and $42.85B in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

โœ“ Pre-computed one-to-many AI Quant brief
๐Ÿค– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists โ€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
๐ŸŽฏ BMY TRADE EXECUTION LEVELS + TODAY'S TOP 3 TRADES EXACT ENTRY โ€ข HARD STOP-LOSS (SUP) โ€ข TARGET (RES) โ€ข WHY

Where to Enter $BMY, Where to Set Your Hard Stop-Loss & Today's Top 3 High-Conviction Trades

๐Ÿ† RECENT ALERT WINNERS: $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
CURRENT TICKER SETUP โ€ข $BMY R/R 2.2 : 1 โ€ข RQD 54/100 (D+)
$BMY
Spot $58.34
1. GET IN (ENTRY)
$57.99โ€“$58.63
2. HARD STOP (SUP)
$55.31 (-5.2%)
3. GET OUT (T1/T2)
$62.13 / $65.05
STOP-LOSS FLOOR (SUP $55.31): Hard stop sits 5.2% below spot to cap downside below key institutional support. If $BMY closes a daily candle below $55.31, step aside.
PROFIT TARGETS (RES $62.13 / $65.05): Scale out 50% at T1 (+6.5%) and trail stop to breakeven for T2 (+11.5%).
Want this $BMY sheet + Today's Top 3 Trades emailed free? Paper Trade $BMY โ†’
โšก TODAY'S TOP 3 SUGGESTED TRADES OF THE DAY (100% FREE CHEAT SHEET) Trade #1 Unlocked โ€ข Enter Email Below to Unblur #2 & #3 + Get $BMY Sheet
#1 โ€ข $ANET R/R 2.6 : 1
Arista Networks Inc.
IN
$164.14
STOP
$154.80
OUT
$178.00
#2 โ€ข ๐Ÿ”’ LOCKED R/R 2.6 : 1
AI Liquid-Cooling Leader
Target: +8.81% to +15.06% | Stop: -5.73%
#3 โ€ข ๐Ÿ”’ LOCKED R/R 2.3 : 1
Cash-Flow Buyback Machine
Target: +6.22% to +10.48% | Stop: -4.52%
INTERACTIVE SCENARIO DECK:
๐Ÿ›ก๏ธ Portfolio Crash X-Ray
EXT / AFTER-HRS: $58.01 (-0.56%)๐Ÿงฌ Cannibal Buyback (-2.64% YoY Shares)โš™๏ธ Cash Engine: 11/20 (D+) โ€ข 26.7% FCF Margin
Verify 90D Bucket Audit โ†’
๐Ÿ“Š Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY โ€ข 51.0% hit rate โ€” wait for RQD โ‰ฅ 70 breakout).
Audit Bucket Track Record โ†’
RQD QUANT TACHOMETERSELL / AVOID โ€ข D+
025507510054
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0โ€“100 RQD rubric) โ€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C ยท Rk D-
Cash (11)Whales (9)SEC (12)Macro (5)CEO (17)
Each axis scored 0โ€“20
12M PRICE TARGET CONE-1.8% Base Target
$72 Bull$57 Base$45 Bear
๐Ÿ“ฌ FREE BMY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: โ€” (No Active Options Snapshot on file for BMY)Realized 20D OHLCV Swing Band: ยฑ5.5%
Deterministic 5-Pillar Attribution (54/100 Composite)
๐Ÿ” WHY BMY SCORES 54/100 (D+) โ€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
โ–ฒ #1 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (31% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy โ€ข Cannibal Buyback (-2.64% YoY Shares)

โ–ฒ #2 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (22% of score)

Altman Z-Score 2.24 (WATCH ZONE (1.8โ€“3.0)) โ€ข Piotroski F-Score 7/9

โ–ผ #1 Drag / Risk Factor: Macro Regime Fit5/20 pts (-15 pt drag)

Macro rate sensitivity & RSI-14 (39.5) create a -15 pt regime headwind

๐Ÿ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 โ†’ Q2 โ†’ Q3 โ†’ Current
Q1 (-3Q)
62
Grade C+$62.48-0.5% Next Q
Q2 (-2Q)
59
Grade C$62.14+2.1% Next Q
Q3 (-1Q)
57
Grade C$63.43-8% Next Q
Current
54
Grade D+$58.34-0.7% Hist 90D ฮฑ
Trajectory: C+ (62) โ†’ D+ (54)Full Audit โ†’
โš”๏ธ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

โš”๏ธ Adversarial Opposing Case: What Could Spark a BMY Turnaround Squeeze

Gideon Ashmere Forensic Desk โ†’

While BMY currently carries a cautious 54/100 (D+) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

๐Ÿš€ Contrarian Squeeze Trigger #1

Company leadership has skin in the game with net positive insider conviction.

๐Ÿš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($61.45) and Max Pain ($61.26) forces dealer call-delta covering toward $72.07.

๐Ÿš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-2.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

๐ŸŽฒ LIVE PREDICTION MARKET ODDS TIED TO $BMYโ€ข $2.4M Crowd Pool โ€ข Kalshi / Polymarket Composite
Contract: โ€œBMY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMAโ€
SEC FORM 4 ร— 13F HEDGE FUNDS ร— CONGRESSIONAL STOCK ACT

BMY Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales โ†’
โ–ฒ Disclosed Buys: 0 ($0)โ–ผ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BMY)

No recent open-market Form 4 cluster sales or emergency dumps flagged on BMY. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP โ€ข SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BMY)

  • โœ“Walkthrough of BMY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • โœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • โœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BMY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.03%๐Ÿ›ก๏ธ HOLDING TREND SUPPORT
2026-11-20O $59.16H $59.81L $58.34C $58.34VOL 12.63M
$69.75$65.14$60.52$55.90$51.29RES $64.87SUP $57.10$58.342026-05-212026-07-082026-08-212026-10-072026-11-20
๐Ÿ›๏ธ GURU-GRADE VALUATION & FORENSIC ACCOUNTING ENGINE NARROW ECONOMIC MOAT (ROIC 13.3% vs WACC 6.6%)

BMY Intrinsic Fair Value Line, Peter Lynch Corridor, Forensic Trio & Warning Signs

1-SECOND VISUAL VALUATION ANCHOR (COMPOSITE DCF + PETER LYNCH + GRAHAM)
Fair Value: $76.80 vs Spot $58.34
SIGNIFICANTLY UNDERVALUED (+24.0%)
Undervalued Zone (< $65) Fair Value Corridor ($65โ€“$88) Overvalued (> $88)
$58
โšก INTERACTIVE 10-YEAR DCF SANDBOX

Test Your Own BMY Growth & WACC Assumptions

YOUR DCF TARGET
$107.93
5-Yr Annual FCF Growth Rate: 10.1%
Discount Rate (WACC Hurdle): 6.6%
Year-10 Terminal FCF Multiple: 16.0x
Margin of Safety: +24.0% vs $58.34 Full DCF Table โ†’
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BMY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
10.9%/yr Implied 5Y Growth

vs. -0.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BMY today. View full Setup Ledger โ†’

๐Ÿฆ‹ Documented & Second-Order Butterfly Connections Open Graph โ†’

No direct multi-tier Butterfly edges indexed yet for BMY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
๐ŸŽฌ No recent verified company-specific video clip queued for BMY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk โ†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT โ€ข SEC EDGAR XBRL ร— RQD PEER BENCHMARK

๐Ÿ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BMY)

1. Head-to-Head Health Care Peer Comparison (BMY vs. SNY, VRTX, GSK, REGN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Bristol-Myers Squibb Company (BMY) ranks #183 by composite RQD confidence (54/100, grade D+) and #20 by equity capitalization ($119.24B). Within this direct 5-issuer industry benchmark cohort, BMY leads on earnings valuation at 17.8x trailing P/E, while VRTX leads on capital efficiency and profitability with 20.0% ROIC and 86.2% gross margin. REGN currently holds the highest overall quantitative score in the immediate peer group at 83/100 (A-) compared with BMY at 54/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BMY ACTIVE
Bristol-Myers Squibb Company
D+ 54/100 17.8x 71.1% 13.3% -2.06% $119.24B Benchmark Subject
SNY
Sanofi ADS
C 62/100 32.8x โ€” 9.9% -2.25% $112.33B /sny-vs-bmy โ†’
VRTX
Vertex Pharmaceuticals Incorporated
B 73/100 34.6x 86.2% 20.0% -2.94% $132.01B /vrtx-vs-bmy โ†’
GSK
GSK plc American
D+ 53/100 32.8x โ€” 9.9% -1.54% $96.75B /gsk-vs-bmy โ†’
REGN
Regeneron Pharmaceuticals Inc.
A- 83/100 18.7x โ€” 9.4% -2.35% $95.52B /regn-vs-bmy โ†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023โ€“FY2025)

SEC EDGAR 10-K โ€ข FILED 2025-12-31 โ€ข CIK 0000014272 โ†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bristol-Myers Squibb Company (BMY) reported GAAP revenue of $48.19B (-0.2% vs. FY2024 revenue of $48.30B , and +7.1% cumulative change since FY2023) , GAAP net income of $7.05B, operating cash flow of $14.16B, and free cash flow of $12.85B (-7.9% YoY). On the balance sheet, BMY closed FY2025 with $90.04B in total assets against $42.85B in total debt (Altman Z-Score: 2.24, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $48.19B $7.05B $14.16B $12.85B $90.04B $42.85B
FY2024 (FY) 2024-12-31 $48.30B -$8.95B $15.19B $13.94B $92.60B $47.60B
FY2023 (FY) 2023-12-31 $45.01B $8.03B $13.86B $11.83B $68.97B $16.14B

3. BMY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

โœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-22, Bristol-Myers Squibb Company (NYSE: BMY) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $58.34 (-2.06% 1D, market cap $119.24B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, BMY ranks #183 in composite RQD confidence.

How does BMY compare to SNY and VRTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BMY carries a Roarable D+ (54/100 RQD), trailing P/E of 17.8x, gross margin of 71.1%, and ROIC of 13.3%. By comparison, SNY (Sanofi ADS) holds a C grade (62/100 RQD, P/E 32.8x, ROIC 9.9%, cap $112.33B) and VRTX (Vertex Pharmaceuticals Incorporated) posts a B grade (73/100 RQD, P/E 34.6x, ROIC 20.0%, cap $132.01B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BMY?

Per BMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000014272), Bristol-Myers Squibb Company generated $48.19B in revenue (-0.2% YoY), $7.05B in net income, and $12.85B in free cash flow against $90.04B in total assets and $42.85B in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BMY trading relative to its 50-day, 200-day, and 52-week technical levels?

BMY last traded at $58.34 (-2.06% on volume of 13,676,891 shares), positioning the stock -5.06% below its 50-day simple moving average ($61.45) and -3.46% below its 200-day simple moving average ($60.43). Across its 52-week range of $47.58 to $68.64, BMY sits at the 51.1% percentile with a 14-day RSI of 39.5 (NEUTRAL RANGE) and an implied next-earnings move of ยฑ5.5% ($55.13 to $61.55).

ROARABLE RATING BRIEF โ€ข RQD 54/100 (D+) โœ“ SEC XBRL & RQD VERIFIED

BMY โ€” Bristol-Myers Squibb Company: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Bristol-Myers Squibb Company (BMY) earns a live Roarable RQD composite score of 54/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $58.34 (-2.06% 1D, market capitalization $119.24B).

  • Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of 13.3%, gross margin of 71.1%, operating margin of 17.9%, and free cash flow yield of 10.24%.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (17/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (12/20): Incorporates a 0.98x equity beta, Altman Z-Score of 2.24, Piotroski F-Score of 7/9, and Debt/Equity of 2.32x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Bristol-Myers Squibb Company is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It carries a market capitalization of $125.4B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Bristol-Myers Squibb Company (BMY) reported $48.19B in annual revenue (up from $48.30B in FY2024, -0.2% YoY) and $7.05B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($45.01B revenue, $8.03B net income) through FY2025, BMY scaled operating cash flow to $14.16B and free cash flow to $12.85B, backed by $90.04B in total assets against $42.85B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • ๐Ÿ‚ Primary Bull Case (D+ โ€ข RQD 54/100): Company leadership has skin in the game with net positive insider conviction. Free cash flow yield of 10.24% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $47.58 โ€“ $68.64 52-week range.
  • ๐Ÿป Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 17.8x trailing P/E and 16.3x EV/EBITDA against 17.9% operating margins and a 0.98x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore โ€” A prospective investor should note that the absence of mapped links means this analysis cannot identify ripple effects from suppliers, customers, or peer companies.

  • Key Question #1: Can BMY sustain or expand its 17.9% operating margin and 13.3% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $48.19B and free cash flow of $12.85B, how will capital allocation balance growth reinvestment against $42.85B in total debt?
  • Key Question #3: How sensitive is BMY's 16.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.98x)?

BMY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Bristol-Myers Squibb Company (BMY) โ€ข Click "Debate This Headline" to argue it in the Roar Pit below

๐Ÿ’ฌ Jump to BMY Debate Forum (3) โ†“
๐Ÿ”ฅ THE ROAR PIT โ€ข LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BMY Bull vs. Bear Conversation Board โ€” What's Your Call at $58.34?

๐Ÿ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BMY ๐Ÿป 33% BEARISH CONVICTION
1. Pick Your Side on BMY:
๐Ÿ’ก Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER โ€ข Cross-Asset Macro Desk ๐Ÿ‚ BULLISH ๐ŸŽฏ Target: $76.85 (+23.0%)
๐Ÿ“Œ Pinned Debate

A 10.24% FCF yield and 13.3% ROIC show strong cash generation, with forward P/E of 16.6 below the trailing 17.8.

The street is overcomplicating Bristol-Myers Squibb Company (BMY). A 10.24% FCF yield and 13.3% ROIC show strong cash generation, with forward P/E of 16.6 below the trailing 17.8.. With an RQD score of 67/100 (C+) and Forensic Balance Sheet at 12/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $67.48.

ArenaChamp_24 ๐Ÿ‚ BULL

@MeanReversion_88 Fair point on 17.8x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (71.1%) holds, EPS grows into the multiple faster than bears think.

ME MeanReversion_88 RQD DEBATE OPENER โ€ข Quantitative Statistical Arb ๐Ÿป BEARISH ๐ŸŽฏ Target: $53.73 (-14.0%)
Spot @ $62.48

Debt/Equity of 2.32 and EV/EBITDA of 16.3 leave the balance sheet leveraged and the enterprise not cheap despite the cash yield.

I respect the product at Bristol-Myers Squibb Company, but the stock at $62.48 is a different story. Debt/Equity of 2.32 and EV/EBITDA of 16.3 leave the balance sheet leveraged and the enterprise not cheap despite the cash yield.. FCF yield is 10.24% and RQD sits at 67/100 (C+) โ€” why pay up here when you can wait for next quarter's numbers?

๐ŸŽฏ DAILY PRE-BELL WATCHLIST โ€ข ENTRY, HARD STOP & TARGET EDUCATIONAL LEVELS ONLY โ€ข EVERY TRADE CARRIES RISK

3 Stocks on Our Radar Today โ€” Entry, Hard Stop & Why

๐Ÿ“Š Recent Paper Examples (Not Typical Real-Money Results): $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
TRADE #1 OF THE DAY R/R 2.6 : 1 โ€ข RQD 88 (A+)
$ANET Arista Networks Inc.
LONG (BUY SETUP)
1. Get In (Entry)
$164.14
2. Hard Stop
$154.80 (-5.7%)
3. Get Out (T1/T2)
$178.00 / $188.50
Entry Rule: Buy between $162.50 โ€“ $165.00 (or on 15-min candle reclaim above $165.40)
Stop Logic: Hard stop at $154.80 sits beneath the 50-day institutional demand shelf and October accumulation baseโ€”capping downside at -5.69% while targeting $178.00 to $188.50 (+14.84%).
4. Why Now: Microsoft (+6.68%) and Amazon (+6.12%) just surged while confirming $320B+ in data-center CapEx, yet passive ETF rebalancing pushed ANET down -2.79% to $164.14. Arista owns the 64.1% gross-margin 800G/1.6T back-end AI Ethernet switching monopoly that cashes those exact hyperscaler checks.
TRADE #2 OF THE DAY R/R 2.6 : 1 โ€ข RQD 86 (A)
๐Ÿ”’ Setup #2: 130kW Direct-to-Chip Liquid Cooling & CDU Thermal Monopoly Pullback
LONG (BUY SETUP)
โ€ข Target Upside: +8.8% (T1) to +15.1% (T2)
โ€ข Max Downside Stop: -5.7% Hard Floor (2.6 : 1 R/R)
Order book sold out through 2027 on key VWAP support. Enter your email below for the ticker, buy trigger, and stop.
TRADE #3 OF THE DAY R/R 2.3 : 1 โ€ข RQD 85 (A)
๐Ÿ”’ Setup #3: 13.27x Forward P/E Money-Center Infrastructure Debt Underwriting Breakout
LONG (BUY SETUP)
โ€ข Target Upside: +6.2% (T1) to +10.5% (T2)
โ€ข Max Downside Stop: -4.5% Hard Floor (2.3 : 1 R/R)
Big-bank infrastructure lender breaking out with a -4.5% stop floor. Enter your email below for the entry zone and target.
โšก See Setups #2 & #3 Right Now + Tomorrow's 3 Setups at 8:00 AM ET
Free impersonal market research. Educational levels only โ€” past setups include losing stops and carry real risk of loss.
2. Guru Strategy Screeners, Formula Hub & Head-to-Head Battles
4. Editorial Investigations, FRED Macro & Interactive Tools
LIVE TAPE